Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Drugs used in the treatment of cardiovascular diseases such as heart failure, heart attack, ischemia and others are eligible for reimbursement. Moreover, regulatory authorities in the UAE are taking initiatives to reduce the treatment cost burden on the patients. For instance, in February 2020, the Ministry of Health and Prevention UAE, reduced the prices of 573 medicines used for treatment of cardiovascular disease, diabetes, nervous and respiratory diseases by 2 to 74%. The initiative would benefit patients who may have insurance with very low annual limits for pharmacy spending.

The UAE Heart Failure Treatment Drugs Market size is estimated to be valued at US$ 62.8 million in 2020 and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027).

Figure 1. UAE Heart Failure Treatment Drugs Market Share (%), by Drug Class, 2020

UAE Heart Failure Drugs Treatment  | Coherent Market Insights

The increasing healthcare expenditure is expected to drive the UAE heart failure treatment drugs market growth during the forecast period. According to Dubai Export 2019, a report prepared by Fitch Solution, Word Bank, and International Trade Center:

  • Pharmaceutical expenditure forecast in UAE for 2019 and 2020 was US$ 5.9 billion and US$ 6.2 billion, respectively.
  • Healthcare expenditure forecast in UAE for 2019 and 2020 was US$ 15.3 billion, and US$ 16.8 billion, respectively.

UAE Heart Failure Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The lockdown in the UAE following the COVID-19 outbreak has placed an economic burden on the private as well as public healthcare sector.

Healthcare providers are facing challenges in terms of declining outpatients’ visits, additional manpower, equipment, consumables, and other resources required to ensure safety in hospitals.

Furthermore, players operating in the heart failure treatment drugs market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include disruption in the supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors of drug products are experiencing irregular demand for products from retailers.

Thus, the COVID-19 pandemic is expected to limit growth of the UAE heart failure treatment drugs market during the forecast period.

request-sample

UAE Heart Failure Treatment Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 62.8 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.5 % 2027 Value Projection: US$ 97.5 Mn
Geographies covered:
  • UAE
Segments covered:
  • By Drug Class: ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Novartis International AG, AstraZeneca Plc., Amgen, Inc., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc., and Teva Pharmaceutical Industries Ltd

Growth Drivers:
  • Increasing healthcare expenditure
Restraints & Challenges:
  • Challenges faced by the pharmaceutical industry in UAE

UAE Heart Failure Treatment Drugs Market: Restraints

Pharmaceutical regulations and guidelines are stricter in Middle Eastern countries such as UAE, Saudi Arabia and others compared to other countries across the world.

Most Middle Eastern pharmaceutical legislation details are not accessible to the public and private pharmaceutical companies across the globe. Moreover, the legislation is only available in the local language, making comprehension difficult for multinational pharmaceutical companies to launch pharmaceutical projects in Middle Eastern countries.

Moreover, pharmaceutical players across the globe have registered fewer products in Middle Eastern countries such as UAE, Saudi Arabia, and others, which may result in limited availability of medicinal products in the countries.

Figure 2. UAE Heart Failure Treatment Drugs Market Value (US$ Mn), 2020

UAE Heart Failure Drugs Treatment  | Coherent Market Insights

Key Players

Major players operating in the UAE Heart Failure Treatment Drugs Market are Novartis International AG, AstraZeneca Plc., Amgen, Inc., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc., and Teva Pharmaceutical Industries Ltd.

Heart failure is characterized by the inability of the heart to pump adequate amount of blood to the body. There are three types of heart failures; left-sided heart failure, right-sided heart failure, and biventricular heart failure. The condition is treated with particular cardiovascular drugs available in the market. Moreover, the treatment for heart failure depends on the stages (stage A, B, C, & D). Drugs such as diuretics, ACE inhibitors, angiotensin 2 receptor blockers, beta blockers, and digitalis are majorly used in the treatment of heart failure.

Various global players are engaged in development of novel therapies and drugs for treating heart failure. In May 2020, AstraZeneca Pharmaceuticals PLC. Received the U.S. Food and Drug Administration’s approval for Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce risk of cardiovascular death and hospitalization for heart failure.

Key features of the study:

  • This report provides in-depth analysis of the UAE heart failure treatment drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the UAE heart failure treatment drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Novartis International AG, AstraZeneca Plc., Amgen, Inc., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc., and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The UAE heart failure treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the UAE heart failure treatment drugs market.

Detailed Segmentation

  • UAE Heart Failure Treatment Drugs Market, By Drug Class:
    • ACE Inhibitors
    • Angiotensin 2 Receptor Blockers
    • Beta Blockers
    • Diuretics
    • Aldosterone Antagonists
    • Inotropes
    • Others
  • UAE Heart Failure Treatment Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Novartis International AG*
      • Company Overview
      • Drug Class Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • AstraZeneca Plc.
    • Amgen, Inc.
    • Pfizer, Inc.
    • Mylan N.V.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb
    • GlaxoSmithKline Plc.
    • Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Impact Analysis
    • Market Opportunities
    • Collaborations and Acquisition
    • Regulatory Scenario
    • Pipeline Analysis
    • Brand Mapping and Pricing Analysis
    • PEST Analysis
    • Reimbursement Scenario
  4. UAE Heart Failure Treatment Drugs Market, Impact of COVID-19 Pandemic
    • Overall Impact on Healthcare Market
  5. UAE Heart Failure Treatment Drugs Market, By Drug Class, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • ACE Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Angiotensin 2 Receptor Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Beta Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Diuretics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Aldosterone Antagonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Inotropes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. UAE Heart Failure Treatment Drugs Market, By Distribution Channel, 2020 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
      • Segment Trends
        • Hospital Pharmacies
          •  Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Retail Pharmacies
          •  Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  7. Competitive Landscape
    • Company Profiles
      • Novartis International AG*
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca Plc.
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen, Inc.
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan N.V.
        •  Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Drug Class Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 06 market data tables and 16 figures on "UAE Heart Failure Treatment Drugs Market – Countrywide Forecast to 2027”.

Frequently Asked Questions

The UAE Heart Failure Treatment Drugs Market size is estimated to be valued at US$ 62.8 million in 2020 and is expected to exhibit a CAGR of 6.5% between 2020 and 2027.
Increasing healthcare expenditure, and high prevalence of heart failure are the major factors driving growth of the UAE heart failure treatment drugs market.
ACE inhibitors is the major product type segment holding the largest market share in the UAE heart failure treatment drugs market.
Hospital pharmacies are major distribution channels holding the largest market share in the UAE heart failure treatment drugs market.
Challenges faced by the pharmaceutical industry in UAE are hampering growth of the market.
Major players operating in the UAE Heart Failure Treatment Drugs Market are Novartis International AG, AstraZeneca Plc., Amgen, Inc., Pfizer, Inc., Mylan N.V., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc., and Teva Pharmaceutical Industries Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner